The German health care system consists of the statutory and private health insurances, whereas the latter covers around 10% of the population. Anyhow, access and commercialization, especially of new and innovative therapies could firstly be introduced through the private system. What are the core differences to follow with such a strategy? What are the specifics of the private health insurances? And are there examples of such a market access pathway? MAP - Market Access Podcast , is the first and only bi-weekly market access podcast provided by MArS. Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de Episode 12 - February 15, 2022